Latest Healthcare Research Reports

Tag: sarcopenia treatment industry

  • Sarcopenia Treatment Market Opportunities Are Emerging Beyond Traditional Growth Areas

    Sarcopenia Treatment Market Opportunities Are Emerging Beyond Traditional Growth Areas

    Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

    Sarcopenia Treatment Market Size Forecast: How Large Could The Market Become By 2030?

    The market for sarcopenia treatments has experienced robust expansion lately, projected to increase from approximately $3.72 billion in 2025 to $3.94 billion in 2026, representing a compound annual growth rate (CAGR) of 5.9 percent. This surge during the past period is a result of several factors, including a burgeoning demographic of older individuals, heightened consciousness regarding muscle deterioration associated with aging, a reliance on established strategies like physical therapy and dietary supplementation, the scarcity of sanctioned pharmacological interventions, and an uptick in disorders affecting mobility.

    The market for sarcopenia treatments is projected to experience robust expansion, reaching an estimated $4.97 billion by 2030 and exhibiting a compound annual growth rate of 6.0% over the coming years. This anticipated growth trajectory is propelled by several key factors, including the ongoing development of innovative pharmacological therapies, a heightened emphasis on early detection and proactive management strategies, increased healthcare investments in the care of the elderly, the escalating incidence of chronic conditions that impact muscle vitality, and a growing number of clinical investigations focused on muscle regeneration. During this forecast period, significant trends are expected to shape the market, such as a greater integration of combined pharmaceutical and exercise-based therapeutic approaches, a noticeable rise in the utilization of nutritional supplements for sarcopenia control, intensified clinical research into myostatin inhibitors and anabolic agents, a growing recognition and diagnosis of sarcopenia among older demographic segments, and a more widespread incorporation of physical therapy within established treatment protocols.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13926&type=smp

    Sarcopenia Treatment Market Growth Momentum: Which Factors Are Influencing Demand?

    A surge in malnutrition is anticipated to be a key driver for the expansion of the sarcopenia treatment market in the future. Malnutrition is characterized by insufficient, excessive, or imbalanced consumption of energy and nutrients, encompassing conditions ranging from undernutrition to being overweight, obese, or developing noncommunicable diseases linked to diet. Treatments for sarcopenia are designed to tackle the concurrent issues of malnutrition and sarcopenia prevalent in elderly individuals, employing strategies like dietary interventions and physical activity to enhance muscle mass, strength, and general nutritional well-being. A compelling example of this trend is the data from January 2025, where the United States Department of Agriculture indicated that 17.9% of households with children experienced food insecurity in 2023, affecting approximately 6.5 million families. Consequently, the increasing prevalence of malnutrition is directly contributing to the growth trajectory of the sarcopenia treatment market.

    Sarcopenia Treatment Market Categorization By Product Type And Application

    The sarcopenia treatment market covered in this report is segmented –

    1) By Treatment Type: Protein Supplements, Vitamin B12 Supplements, Vitamin D And Calcium Supplements, Other Treatment Types

    2) By Type: Primary Sarcopenia, Secondary Sarcopenia

    3) By Route Of Administration: Oral, Parenteral, Enteral

    4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

    Subsegments:

    1) By Protein Supplements: Whey Protein, Casein Protein, Soy Protein, Plant-Based Protein

    2) By Vitamin B12 Supplements: Cyanocobalamin, Methylcobalamin

    3) By Vitamin D And Calcium Supplements: Vitamin D2, Vitamin D3, Calcium Carbonate, Calcium Citrate

    4) By Other Treatment Types: Exercise Programs, Hormone Replacement Therapy, Other Nutritional Interventions

    Sarcopenia Treatment Market Trends Reshaping Industry Growth

    Leading pharmaceutical and biotechnology firms in the sarcopenia treatment sector are intensifying their efforts to develop and investigate a range of innovative therapeutic approaches to enhance patient care. The underlying purpose of a clinical study involves a disciplined inquiry using human participants to rigorously assess the safety, effectiveness, and ultimate results of a medical intervention. A compelling example of this commitment is the September 2023 announcement from Biophytis, a French life sciences enterprise, regarding its receipt of Food and Drug Administration (FDA) approval to commence the SARA-31 Phase 3 investigation for sarcopenia. This particular trial is designed to scrutinize the therapeutic value and safety profile of Sarconeos (BIO101) when administered to individuals diagnosed with sarcopenia who exhibit a heightened susceptibility to motor function impairment. This initiative represents a substantial leap forward in both technological innovation and pharmaceutical treatment strategies, presenting potential advantages in efficacy and safety for those afflicted with severe forms of sarcopenia, and notably, stands as the inaugural phase 3 trial in this specific disease area to gain FDA clearance. The investigation is projected to enroll approximately 900 participants, all exceeding 65 years of age and exhibiting characteristics of sarcopenia, such as diminished walking velocity and reduced handgrip strength. Key metrics for measuring success, serving as primary endpoints, will encompass the evaluation of major mobility disability (MMD) risk, walking speed, handgrip strength, and the subjective experience of patient-reported quality of life.

    Sarcopenia Treatment Market Company Landscape And Strategic Competition

    Major companies operating in the sarcopenia treatment market are Pfizer Inc, F Hoffmann La Roche, Merck Sharp And Dohme Corp, AbbVie Inc, Bayer AG, Novartis AG, Sanofi SA, Abbott Laboratories Inc, GlaxoSmithKline plc, Eli Lilly And Company, BASF SE, Nestle Health Science, Haleon Group Of Companies, DSM, Amway Corporation, Perrigo Company PLC, Intas Pharmaceuticals Ltd, Zydus Lifesciences, Fermenta Biotech Limited, Metagenics LLC, Makers Nutrition LLC, NutraScience Labs, AstaReal AB, NutraPak USA, BioThrive Sciences, Wellona Pharma, Healing Pharma India Pvt Ltd, Nutrafill

    Access The Complete Sarcopenia Treatment Market Report:

    https://www.thebusinessresearchcompany.com/report/sarcopenia-treatment-global-market-report

    Sarcopenia Treatment Market Regional Analysis And Leading Geography

    North Americawas the largest region in the sarcopenia treatment market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the sarcopenia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Digital Therapeutics Sarcopenia Market Opportunities Are Emerging Beyond Traditional Growth Areas

    Digital Therapeutics Sarcopenia Market Opportunities Are Emerging Beyond Traditional Growth Areas

    Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

    Digital Therapeutics Sarcopenia Market Size Outlook: How Fast Will Revenue Grow Through 2030?

    The market for digital therapeutics targeting sarcopenia has experienced significant expansion recently, with projections indicating a rise from $1.54 billion in 2025 to $1.78 billion by 2026, reflecting a compound annual growth rate of 16.1%. This historical growth trajectory has been bolstered by several key factors, including the increasing prevalence of an aging global population, heightened awareness concerning the health implications of sarcopenia, a growing trend in the adoption of telehealth services, the increasing acceptance of therapeutic solutions delivered via software, and the initial positive outcomes from clinical trials involving digital interventions.

    The digital therapeutics market focused on sarcopenia is poised for swift expansion in the upcoming years, projecting a rise to $3.21 billion by 2030, underpinned by a compound annual growth rate (CAGR) of 15.9%. This anticipated growth over the forecast period stems from several key drivers, including a heightened need for managing chronic conditions from home, the increasing incorporation of AI for personalized therapeutic approaches, broader availability of reimbursement for digital health solutions, a greater uptake of remote patient monitoring technologies, and a pronounced emphasis on proactive measures for muscle health. During this same forecast period, significant trends are expected to emerge, such as the wider adoption of individualized digital therapy plans, increased utilization of wearable devices for muscle monitoring, a greater deployment of remote physiotherapy services, the expansion of data-informed strategies for sarcopenia management, and a reinforced focus on engaging patients and ensuring they adhere to their treatment regimens.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=27278&type=smp

    Digital Therapeutics Sarcopenia Market Growth Momentum: Which Factors Are Influencing Demand?

    The increasing incidence of co-occurring health issues is anticipated to be a primary catalyst for the expansion of the digital therapeutics market focused on sarcopenia. These co-occurring conditions, known as comorbidities, involve the simultaneous presence of multiple diseases within one person. Factors such as an aging global population contribute significantly to this rise, as older age groups are more susceptible to developing several chronic ailments due to diminished bodily functions and prolonged exposure to various health hazards. Digital therapeutic solutions designed for sarcopenia offer a valuable approach to mitigating comorbidities, particularly obesity, by encouraging consistent exercise and muscle enhancement activities, thereby aiding metabolic function and curbing excess body fat. Illustrating this trend, by 2035, an estimated 79% of adults grappling with being overweight or obese will reside in lower and middle-income countries, with the global adult population affected by obesity projected to reach 1.53 billion, as reported by the World Obesity Federation in March 2024. Consequently, the growing burden of comorbidities plays a crucial role in fueling the digital therapeutics sarcopenia market’s advancement.

    Digital Therapeutics Sarcopenia Market Segmentation Trends And Revenue Drivers

    The digital therapeutics sarcopenia market covered in this report is segmented –

    1) By Product: Software, Devices, Services

    2) By Distribution Channel: Online Platforms, Direct-To-Consumer Digital Channels, Other Distribution Channels

    3) By Application: Muscle Strengthening, Physical Activity Monitoring, Nutrition Management, Other Applications

    4) By End User: Hospitals And Clinics, Homecare Settings, Rehabilitation Centers, Other End Users

    Subsegments:

    1) By Software: Mobile Applications, Web-Based Platforms, AI-Powered Monitoring Tools, Exercise And Rehabilitation Programs, Nutritional Guidance Software

    2) By Devices: Wearable Fitness Trackers, Smart Scales, Connected Resistance Bands, Electromyography (EMG) Devices, Muscle Strength Assessment Tools

    3) By Services: Remote Patient Monitoring Services, Virtual Physiotherapy Sessions, Teleconsultation Services, Personalized Coaching Services, Data Analytics And Reporting Services

    Digital Therapeutics Sarcopenia Market Trends Reshaping Industry Growth

    In the digital therapeutics market for sarcopenia, leading entities are prioritizing the creation of sophisticated technologies, including drug discovery platforms, with the aim of formulating more precise treatments, boosting therapeutic outcomes, and expediting the provision of individualized care for the decline in muscle mass associated with aging. Such platforms are instrumental in expediting the identification and development of novel pharmaceuticals through the utilization of cutting-edge instruments and techniques. To illustrate, in April 2025, ProFuse Technology, a biotechnology firm headquartered in Israel, introduced an innovative drug discovery platform designed to mitigate muscle deterioration stemming from GLP-1 based weight-loss medications, the natural aging process (sarcopenia), and cancer-related wasting (cachexia). By employing laboratory-cultivated, exceptionally mature muscle tissues that closely replicate in-vivo muscle, the company facilitates rapid and efficient testing and evaluation of potential drug compounds. This sophisticated platform not only lessens the necessity for animal experimentation but also curtails research expenditures. With a growing demand for therapies that preserve muscle mass, ProFuse is diversifying from its cultivated meat ventures into the biopharmaceutical sector, presenting a pioneering strategy to confront the escalating challenges in maintaining muscle health.

    #Digital Therapeutics Sarcopenia Market Industry Leaders: Which Organizations Are Driving Competition?

    Major companies operating in the digital therapeutics sarcopenia market are Sword Health Inc., Biofourmis Inc., Hinge Health Inc., Omada Health Inc., Evolv Rehabilitation Technologies Ltd., Click Therapeutics Inc., DarioHealth Corp., WellDoc Inc., Lark Technologies Inc., Kaia Health Software GmbH, Liva Healthcare A/S, Zibrio Inc., Gait Up SA, Noraxon Inc., Mira Rehab Limited, Cometa Srl., Koneksa Health Inc., Physitrack PLC, Kaia Health Inc., XRHealth USA Inc., MedRhythms Inc.

    Access The Complete Digital Therapeutics Sarcopenia Market Report:

    https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

    Digital Therapeutics Sarcopenia Market Geographic Distribution And Regional Opportunities

    North Americawas the largest region in the digital therapeutics sarcopenia market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the digital therapeutics sarcopenia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Digital Therapeutics Sarcopenia Market Opportunities Are Emerging Beyond Traditional Growth Areas

    Digital Therapeutics Sarcopenia Market Opportunities Are Emerging Beyond Traditional Growth Areas

    Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

    Digital Therapeutics Sarcopenia Market Size Outlook: How Fast Will Revenue Grow Through 2030?

    The market for digital therapeutics targeting sarcopenia has experienced significant expansion recently, with projections indicating a rise from $1.54 billion in 2025 to $1.78 billion by 2026, reflecting a compound annual growth rate of 16.1%. This historical growth trajectory has been bolstered by several key factors, including the increasing prevalence of an aging global population, heightened awareness concerning the health implications of sarcopenia, a growing trend in the adoption of telehealth services, the increasing acceptance of therapeutic solutions delivered via software, and the initial positive outcomes from clinical trials involving digital interventions.

    The digital therapeutics market focused on sarcopenia is poised for swift expansion in the upcoming years, projecting a rise to $3.21 billion by 2030, underpinned by a compound annual growth rate (CAGR) of 15.9%. This anticipated growth over the forecast period stems from several key drivers, including a heightened need for managing chronic conditions from home, the increasing incorporation of AI for personalized therapeutic approaches, broader availability of reimbursement for digital health solutions, a greater uptake of remote patient monitoring technologies, and a pronounced emphasis on proactive measures for muscle health. During this same forecast period, significant trends are expected to emerge, such as the wider adoption of individualized digital therapy plans, increased utilization of wearable devices for muscle monitoring, a greater deployment of remote physiotherapy services, the expansion of data-informed strategies for sarcopenia management, and a reinforced focus on engaging patients and ensuring they adhere to their treatment regimens.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=27278&type=smp

    Digital Therapeutics Sarcopenia Market Growth Momentum: Which Factors Are Influencing Demand?

    The increasing incidence of co-occurring health issues is anticipated to be a primary catalyst for the expansion of the digital therapeutics market focused on sarcopenia. These co-occurring conditions, known as comorbidities, involve the simultaneous presence of multiple diseases within one person. Factors such as an aging global population contribute significantly to this rise, as older age groups are more susceptible to developing several chronic ailments due to diminished bodily functions and prolonged exposure to various health hazards. Digital therapeutic solutions designed for sarcopenia offer a valuable approach to mitigating comorbidities, particularly obesity, by encouraging consistent exercise and muscle enhancement activities, thereby aiding metabolic function and curbing excess body fat. Illustrating this trend, by 2035, an estimated 79% of adults grappling with being overweight or obese will reside in lower and middle-income countries, with the global adult population affected by obesity projected to reach 1.53 billion, as reported by the World Obesity Federation in March 2024. Consequently, the growing burden of comorbidities plays a crucial role in fueling the digital therapeutics sarcopenia market’s advancement.

    Digital Therapeutics Sarcopenia Market Segmentation Trends And Revenue Drivers

    The digital therapeutics sarcopenia market covered in this report is segmented –

    1) By Product: Software, Devices, Services

    2) By Distribution Channel: Online Platforms, Direct-To-Consumer Digital Channels, Other Distribution Channels

    3) By Application: Muscle Strengthening, Physical Activity Monitoring, Nutrition Management, Other Applications

    4) By End User: Hospitals And Clinics, Homecare Settings, Rehabilitation Centers, Other End Users

    Subsegments:

    1) By Software: Mobile Applications, Web-Based Platforms, AI-Powered Monitoring Tools, Exercise And Rehabilitation Programs, Nutritional Guidance Software

    2) By Devices: Wearable Fitness Trackers, Smart Scales, Connected Resistance Bands, Electromyography (EMG) Devices, Muscle Strength Assessment Tools

    3) By Services: Remote Patient Monitoring Services, Virtual Physiotherapy Sessions, Teleconsultation Services, Personalized Coaching Services, Data Analytics And Reporting Services

    Digital Therapeutics Sarcopenia Market Trends Reshaping Industry Growth

    In the digital therapeutics market for sarcopenia, leading entities are prioritizing the creation of sophisticated technologies, including drug discovery platforms, with the aim of formulating more precise treatments, boosting therapeutic outcomes, and expediting the provision of individualized care for the decline in muscle mass associated with aging. Such platforms are instrumental in expediting the identification and development of novel pharmaceuticals through the utilization of cutting-edge instruments and techniques. To illustrate, in April 2025, ProFuse Technology, a biotechnology firm headquartered in Israel, introduced an innovative drug discovery platform designed to mitigate muscle deterioration stemming from GLP-1 based weight-loss medications, the natural aging process (sarcopenia), and cancer-related wasting (cachexia). By employing laboratory-cultivated, exceptionally mature muscle tissues that closely replicate in-vivo muscle, the company facilitates rapid and efficient testing and evaluation of potential drug compounds. This sophisticated platform not only lessens the necessity for animal experimentation but also curtails research expenditures. With a growing demand for therapies that preserve muscle mass, ProFuse is diversifying from its cultivated meat ventures into the biopharmaceutical sector, presenting a pioneering strategy to confront the escalating challenges in maintaining muscle health.

    #Digital Therapeutics Sarcopenia Market Industry Leaders: Which Organizations Are Driving Competition?

    Major companies operating in the digital therapeutics sarcopenia market are Sword Health Inc., Biofourmis Inc., Hinge Health Inc., Omada Health Inc., Evolv Rehabilitation Technologies Ltd., Click Therapeutics Inc., DarioHealth Corp., WellDoc Inc., Lark Technologies Inc., Kaia Health Software GmbH, Liva Healthcare A/S, Zibrio Inc., Gait Up SA, Noraxon Inc., Mira Rehab Limited, Cometa Srl., Koneksa Health Inc., Physitrack PLC, Kaia Health Inc., XRHealth USA Inc., MedRhythms Inc.

    Access The Complete Digital Therapeutics Sarcopenia Market Report:

    https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

    Digital Therapeutics Sarcopenia Market Geographic Distribution And Regional Opportunities

    North Americawas the largest region in the digital therapeutics sarcopenia market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the digital therapeutics sarcopenia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Digital Therapeutics Sarcopenia Market Opportunities Are Emerging Beyond Traditional Growth Areas

    Digital Therapeutics Sarcopenia Market Opportunities Are Emerging Beyond Traditional Growth Areas

    Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

    Digital Therapeutics Sarcopenia Market Size Outlook: How Fast Will Revenue Grow Through 2030?

    The market for digital therapeutics targeting sarcopenia has experienced significant expansion recently, with projections indicating a rise from $1.54 billion in 2025 to $1.78 billion by 2026, reflecting a compound annual growth rate of 16.1%. This historical growth trajectory has been bolstered by several key factors, including the increasing prevalence of an aging global population, heightened awareness concerning the health implications of sarcopenia, a growing trend in the adoption of telehealth services, the increasing acceptance of therapeutic solutions delivered via software, and the initial positive outcomes from clinical trials involving digital interventions.

    The digital therapeutics market focused on sarcopenia is poised for swift expansion in the upcoming years, projecting a rise to $3.21 billion by 2030, underpinned by a compound annual growth rate (CAGR) of 15.9%. This anticipated growth over the forecast period stems from several key drivers, including a heightened need for managing chronic conditions from home, the increasing incorporation of AI for personalized therapeutic approaches, broader availability of reimbursement for digital health solutions, a greater uptake of remote patient monitoring technologies, and a pronounced emphasis on proactive measures for muscle health. During this same forecast period, significant trends are expected to emerge, such as the wider adoption of individualized digital therapy plans, increased utilization of wearable devices for muscle monitoring, a greater deployment of remote physiotherapy services, the expansion of data-informed strategies for sarcopenia management, and a reinforced focus on engaging patients and ensuring they adhere to their treatment regimens.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=27278&type=smp

    Digital Therapeutics Sarcopenia Market Growth Momentum: Which Factors Are Influencing Demand?

    The increasing incidence of co-occurring health issues is anticipated to be a primary catalyst for the expansion of the digital therapeutics market focused on sarcopenia. These co-occurring conditions, known as comorbidities, involve the simultaneous presence of multiple diseases within one person. Factors such as an aging global population contribute significantly to this rise, as older age groups are more susceptible to developing several chronic ailments due to diminished bodily functions and prolonged exposure to various health hazards. Digital therapeutic solutions designed for sarcopenia offer a valuable approach to mitigating comorbidities, particularly obesity, by encouraging consistent exercise and muscle enhancement activities, thereby aiding metabolic function and curbing excess body fat. Illustrating this trend, by 2035, an estimated 79% of adults grappling with being overweight or obese will reside in lower and middle-income countries, with the global adult population affected by obesity projected to reach 1.53 billion, as reported by the World Obesity Federation in March 2024. Consequently, the growing burden of comorbidities plays a crucial role in fueling the digital therapeutics sarcopenia market’s advancement.

    Digital Therapeutics Sarcopenia Market Segmentation Trends And Revenue Drivers

    The digital therapeutics sarcopenia market covered in this report is segmented –

    1) By Product: Software, Devices, Services

    2) By Distribution Channel: Online Platforms, Direct-To-Consumer Digital Channels, Other Distribution Channels

    3) By Application: Muscle Strengthening, Physical Activity Monitoring, Nutrition Management, Other Applications

    4) By End User: Hospitals And Clinics, Homecare Settings, Rehabilitation Centers, Other End Users

    Subsegments:

    1) By Software: Mobile Applications, Web-Based Platforms, AI-Powered Monitoring Tools, Exercise And Rehabilitation Programs, Nutritional Guidance Software

    2) By Devices: Wearable Fitness Trackers, Smart Scales, Connected Resistance Bands, Electromyography (EMG) Devices, Muscle Strength Assessment Tools

    3) By Services: Remote Patient Monitoring Services, Virtual Physiotherapy Sessions, Teleconsultation Services, Personalized Coaching Services, Data Analytics And Reporting Services

    Digital Therapeutics Sarcopenia Market Trends Reshaping Industry Growth

    In the digital therapeutics market for sarcopenia, leading entities are prioritizing the creation of sophisticated technologies, including drug discovery platforms, with the aim of formulating more precise treatments, boosting therapeutic outcomes, and expediting the provision of individualized care for the decline in muscle mass associated with aging. Such platforms are instrumental in expediting the identification and development of novel pharmaceuticals through the utilization of cutting-edge instruments and techniques. To illustrate, in April 2025, ProFuse Technology, a biotechnology firm headquartered in Israel, introduced an innovative drug discovery platform designed to mitigate muscle deterioration stemming from GLP-1 based weight-loss medications, the natural aging process (sarcopenia), and cancer-related wasting (cachexia). By employing laboratory-cultivated, exceptionally mature muscle tissues that closely replicate in-vivo muscle, the company facilitates rapid and efficient testing and evaluation of potential drug compounds. This sophisticated platform not only lessens the necessity for animal experimentation but also curtails research expenditures. With a growing demand for therapies that preserve muscle mass, ProFuse is diversifying from its cultivated meat ventures into the biopharmaceutical sector, presenting a pioneering strategy to confront the escalating challenges in maintaining muscle health.

    #Digital Therapeutics Sarcopenia Market Industry Leaders: Which Organizations Are Driving Competition?

    Major companies operating in the digital therapeutics sarcopenia market are Sword Health Inc., Biofourmis Inc., Hinge Health Inc., Omada Health Inc., Evolv Rehabilitation Technologies Ltd., Click Therapeutics Inc., DarioHealth Corp., WellDoc Inc., Lark Technologies Inc., Kaia Health Software GmbH, Liva Healthcare A/S, Zibrio Inc., Gait Up SA, Noraxon Inc., Mira Rehab Limited, Cometa Srl., Koneksa Health Inc., Physitrack PLC, Kaia Health Inc., XRHealth USA Inc., MedRhythms Inc.

    Access The Complete Digital Therapeutics Sarcopenia Market Report:

    https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

    Digital Therapeutics Sarcopenia Market Geographic Distribution And Regional Opportunities

    North Americawas the largest region in the digital therapeutics sarcopenia market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the digital therapeutics sarcopenia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global sarcopenia treatment market to hit $4.97 billion by 2030 at 6% CAGR

    Global sarcopenia treatment market to hit $4.97 billion by 2030 at 6% CAGR

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Is The Projected Increase In Market Value Of The Sarcopenia Treatment Market During 2026–2030?

    The sarcopenia treatment market has experienced strong growth in recent years. It is projected to expand from $3.72 billion in 2025 to $3.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.9%. The growth observed in the past can be attributed to factors such as an expanding elderly population base, increasing awareness of age-related muscle loss, reliance on physical therapy and nutritional support, the limited availability of approved drug therapies, and a rising incidence of mobility-related disorders.

    The sarcopenia treatment market is projected for significant expansion in the coming years, anticipated to reach $4.97 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.0%. This growth during the forecast period is attributable to several factors, including the emergence of innovative pharmacological therapies, a heightened emphasis on prompt diagnosis and intervention, increasing healthcare expenditure dedicated to geriatric care, the escalating incidence of chronic illnesses impacting muscle health, and the expansion of clinical trials aimed at muscle regeneration. Key trends expected within the forecast period encompass a greater utilization of integrated pharmacological and exercise-based approaches, the increasing incorporation of nutritional supplements in managing sarcopenia, an uptick in clinical investigations into myostatin inhibitors and anabolic agents, enhanced identification of sarcopenia among older adults, and a broader integration of physical therapy into treatment protocols.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13926&type=smp

    What Major Factors Are Driving The Sarcopenia Treatment Market Forward?

    The sarcopenia treatment market is anticipated to grow as a result of increasing malnutrition. Malnutrition refers to deficiencies, excesses, or imbalances in an individual’s consumption of energy and nutrients, encompassing both undernutrition and conditions such as overweight, obesity, and diet-related noncommunicable diseases. Sarcopenia treatment addresses the simultaneous presence of malnutrition and sarcopenia in older adults via interventions like nutritional therapy and exercise, aiming to improve muscle mass, strength, and overall nutritional status. For instance, in January 2025, according to a report published by the United States Department of Agriculture, a US-based government department, household food insecurity affected 17.9% of families with children in 2023, impacting roughly 6.5 million such households. Consequently, the rise in malnutrition is propelling the expansion of the sarcopenia treatment market.

    What Are The Main Segments Within The Sarcopenia Treatment Market Segment Structure?

    The sarcopenia treatment market covered in this report is segmented –

    1) By Treatment Type: Protein Supplements, Vitamin B12 Supplements, Vitamin D And Calcium Supplements, Other Treatment Types

    2) By Type: Primary Sarcopenia, Secondary Sarcopenia

    3) By Route Of Administration: Oral, Parenteral, Enteral

    4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

    Subsegments:

    1) By Protein Supplements: Whey Protein, Casein Protein, Soy Protein, Plant-Based Protein

    2) By Vitamin B12 Supplements: Cyanocobalamin, Methylcobalamin

    3) By Vitamin D And Calcium Supplements: Vitamin D2, Vitamin D3, Calcium Carbonate, Calcium Citrate

    4) By Other Treatment Types: Exercise Programs, Hormone Replacement Therapy, Other Nutritional Interventions

    Which Trends Are Impacting The Progress Of The Sarcopenia Treatment Market?

    Companies operating within the sarcopenia treatment market are increasingly directing their efforts towards developing numerous advanced clinical study options to ensure superior treatment choices. A clinical study represents a systematic investigation conducted on human participants to assess the safety, effectiveness, or outcomes of a medical intervention. For instance, in September 2023, Biophytis, a France-based biotechnology company, announced that the Food and Drug Administration (FDA) authorized the initiation of the SARA-31 Phase 3 study for sarcopenia. This study aims to evaluate the efficacy and safety of Sarconeos (BIO101) in treating sarcopenic patients who are at risk of motor disability. This particular study signifies a substantial advance in technological and pharmaceutical treatment approaches, potentially offering benefits in both efficacy and safety for individuals with severe sarcopenia. It holds the distinction of being the first-ever Phase 3 study in sarcopenia and has received FDA authorization. The study is planned to include approximately 900 patients over 65 years old who have sarcopenia, low walking speed, and low hand grip strength. The primary endpoint will be the evaluation of the risk of major mobility disability (MMD), along with walking speed, hand grip strength, and patient-reported quality of life.

    Who Are The Companies Participating In The Sarcopenia Treatment Market?

    Major companies operating in the sarcopenia treatment market are Pfizer Inc, F Hoffmann La Roche, Merck Sharp And Dohme Corp, AbbVie Inc, Bayer AG, Novartis AG, Sanofi SA, Abbott Laboratories Inc, GlaxoSmithKline plc, Eli Lilly And Company, BASF SE, Nestle Health Science, Haleon Group Of Companies, DSM, Amway Corporation, Perrigo Company PLC, Intas Pharmaceuticals Ltd, Zydus Lifesciences, Fermenta Biotech Limited, Metagenics LLC, Makers Nutrition LLC, NutraScience Labs, AstaReal AB, NutraPak USA, BioThrive Sciences, Wellona Pharma, Healing Pharma India Pvt Ltd, Nutrafill

    Get The Full Sarcopenia Treatment Market Report:

    https://www.thebusinessresearchcompany.com/report/sarcopenia-treatment-global-market-report

    Which Region Is The Leading Market For The Sarcopenia Treatment Market?

    North America was the largest region in the sarcopenia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sarcopenia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Sarcopenia Treatment Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/sarcopenia-treatment-global-market-report

    Browse Through More Reports Similar to the Global Sarcopenia Treatment Market 2026, By The Business Research Company

    Sarcoma Drugs Market Report 2026

    https://www.thebusinessresearchcompany.com/report/sarcoma-drugs-global-market-report

    Congenital Diaphragmatic Hernia Drugs Market Report

    https://www.thebusinessresearchcompany.com/report/congenital-diaphragmatic-hernia-drugs-global-market-report

    Vulvodynia Treatment Market Report

    https://www.thebusinessresearchcompany.com/report/vulvodynia-treatment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Digital Therapeutics for Sarcopenia Market to Reach $3.21B by 2030

    Digital Therapeutics for Sarcopenia Market to Reach $3.21B by 2030

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Is The Estimated Market Size Of The Digital Therapeutics Sarcopenia Market In 2026, And How Will Its Value Evolve By 2030?

    The digital therapeutics sarcopenia market size has seen rapid expansion in recent years. It is anticipated to increase from $1.54 billion in 2025 to $1.78 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 16.1%. The growth observed historically can be ascribed to elements such as the increasing prevalence of an aging population, heightened awareness of health risks linked to sarcopenia, the expansion of telehealth adoption, increasing acceptance of software-based medical therapies, and the early clinical validation of digital interventions.

    The digital therapeutics sarcopenia market size is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $3.21 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.9%. This projected growth throughout the forecast period stems from factors such as the heightened demand for home-based care for chronic conditions, the escalating incorporation of AI-powered personalized therapies, broadened reimbursement avenues for digital therapeutics, the expanding uptake of remote patient monitoring, and a reinforced emphasis on solutions for preventive muscle health. Key trends anticipated during this period encompass the wider acceptance of tailored digital therapy programs, the increased utilization of wearable devices for muscle monitoring, the broader implementation of remote physiotherapy platforms, the development of data-informed sarcopenia management strategies, and a stronger commitment to patient involvement and compliance.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

    What Major Factors Are Driving The Digital Therapeutics Sarcopenia Market Forward?

    The expanding presence of comorbidities is anticipated to fuel the expansion of the digital therapeutics sarcopenia market. Comorbidities are defined as the concurrent existence of multiple health conditions within a single individual. The increase in comorbidities stems from an aging demographic, as older age raises the probability of developing several chronic ailments due to diminishing physiological functions and extended exposure to various health hazards. Digital therapeutics designed for sarcopenia offer advantages in averting comorbidities, particularly obesity, by fostering consistent physical activity and muscle reinforcement, which aids in enhancing metabolism and minimizing fat accumulation. For example, data from March 2024, provided by the World Obesity Federation, a membership body based in the UK, projects that nearly 79% of adults impacted by overweight and obesity will reside in low- and middle-income nations by 2035, with the total count of obese adults forecast to reach 1.53 billion. Consequently, the increasing incidence of comorbidities is propelling the growth of the digital therapeutics sarcopenia market.

    How Are Segments Identified Within The Digital Therapeutics Sarcopenia Market Segment Framework?

    The digital therapeutics sarcopenia market covered in this report is segmented –

    1) By Product: Software, Devices, Services

    2) By Distribution Channel: Online Platforms, Direct-To-Consumer Digital Channels, Other Distribution Channels

    3) By Application: Muscle Strengthening, Physical Activity Monitoring, Nutrition Management, Other Applications

    4) By End User: Hospitals And Clinics, Homecare Settings, Rehabilitation Centers, Other End Users

    Subsegments:

    1) By Software: Mobile Applications, Web-Based Platforms, AI-Powered Monitoring Tools, Exercise And Rehabilitation Programs, Nutritional Guidance Software

    2) By Devices: Wearable Fitness Trackers, Smart Scales, Connected Resistance Bands, Electromyography (EMG) Devices, Muscle Strength Assessment Tools

    3) By Services: Remote Patient Monitoring Services, Virtual Physiotherapy Sessions, Teleconsultation Services, Personalized Coaching Services, Data Analytics And Reporting Services

    Which Trends Are Impacting The Progress Of The Digital Therapeutics Sarcopenia Market?

    Leading companies in the digital therapeutics sarcopenia market are concentrating on developing sophisticated solutions, such as drug discovery platforms. Their objective is to create more targeted therapies, improve treatment effectiveness, and accelerate the provision of personalized care for age-related muscle loss. A drug discovery platform aids in the quicker and more effective identification and creation of new drugs through advanced tools and methods. For example, in April 2025, ProFuse Technology, an Israel-based biotechnology company, unveiled a new drug discovery platform aimed at preventing muscle loss induced by GLP-1 weight-loss drugs, aging (sarcopenia), and cancer cachexia. By employing lab-grown, highly mature muscle tissues that accurately imitate natural muscle, the company can precisely test and screen drug candidates with enhanced speed and efficiency. This advanced platform reduces the dependence on animal testing and decreases research expenses. As the demand for muscle-preserving therapies rises, ProFuse is broadening its scope beyond cultivated meat into the biopharmaceutical industry, offering a pioneering strategy to address increasingly complex muscle health issues.

    Who Are The Companies Competing Within The Digital Therapeutics Sarcopenia Market?

    Major companies operating in the digital therapeutics sarcopenia market are Sword Health Inc., Biofourmis Inc., Hinge Health Inc., Omada Health Inc., Evolv Rehabilitation Technologies Ltd., Click Therapeutics Inc., DarioHealth Corp., WellDoc Inc., Lark Technologies Inc., Kaia Health Software GmbH, Liva Healthcare A/S, Zibrio Inc., Gait Up SA, Noraxon Inc., Mira Rehab Limited, Cometa Srl., Koneksa Health Inc., Physitrack PLC, Kaia Health Inc., XRHealth USA Inc., MedRhythms Inc.

    Get The Full Digital Therapeutics Sarcopenia Market Report:

    https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

    Which Region Leads The Digital Therapeutics Sarcopenia Market In Overall Market Size?

    North America was the largest region in the digital therapeutics sarcopenia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital therapeutics sarcopenia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Digital Therapeutics Sarcopenia Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

    Browse Through More Reports Similar to the Global Digital Therapeutics Sarcopenia Market 2026, By The Business Research Company

    Battery Separators Market Report 2026

    https://www.thebusinessresearchcompany.com/report/battery-separators-global-market-report

    Cutter Stapler Market Report 2026

    https://www.thebusinessresearchcompany.com/report/cutter-stapler-global-market-report

    Battery Manufacturing Equipment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/battery-manufacturing-equipment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Digital Therapeutics for Sarcopenia Market to Reach $3.21B by 2030

    Digital Therapeutics for Sarcopenia Market to Reach $3.21B by 2030

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Is The Estimated Market Size Of The Digital Therapeutics Sarcopenia Market In 2026, And How Will Its Value Evolve By 2030?

    The digital therapeutics sarcopenia market size has seen rapid expansion in recent years. It is anticipated to increase from $1.54 billion in 2025 to $1.78 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 16.1%. The growth observed historically can be ascribed to elements such as the increasing prevalence of an aging population, heightened awareness of health risks linked to sarcopenia, the expansion of telehealth adoption, increasing acceptance of software-based medical therapies, and the early clinical validation of digital interventions.

    The digital therapeutics sarcopenia market size is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $3.21 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.9%. This projected growth throughout the forecast period stems from factors such as the heightened demand for home-based care for chronic conditions, the escalating incorporation of AI-powered personalized therapies, broadened reimbursement avenues for digital therapeutics, the expanding uptake of remote patient monitoring, and a reinforced emphasis on solutions for preventive muscle health. Key trends anticipated during this period encompass the wider acceptance of tailored digital therapy programs, the increased utilization of wearable devices for muscle monitoring, the broader implementation of remote physiotherapy platforms, the development of data-informed sarcopenia management strategies, and a stronger commitment to patient involvement and compliance.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

    What Major Factors Are Driving The Digital Therapeutics Sarcopenia Market Forward?

    The expanding presence of comorbidities is anticipated to fuel the expansion of the digital therapeutics sarcopenia market. Comorbidities are defined as the concurrent existence of multiple health conditions within a single individual. The increase in comorbidities stems from an aging demographic, as older age raises the probability of developing several chronic ailments due to diminishing physiological functions and extended exposure to various health hazards. Digital therapeutics designed for sarcopenia offer advantages in averting comorbidities, particularly obesity, by fostering consistent physical activity and muscle reinforcement, which aids in enhancing metabolism and minimizing fat accumulation. For example, data from March 2024, provided by the World Obesity Federation, a membership body based in the UK, projects that nearly 79% of adults impacted by overweight and obesity will reside in low- and middle-income nations by 2035, with the total count of obese adults forecast to reach 1.53 billion. Consequently, the increasing incidence of comorbidities is propelling the growth of the digital therapeutics sarcopenia market.

    How Are Segments Identified Within The Digital Therapeutics Sarcopenia Market Segment Framework?

    The digital therapeutics sarcopenia market covered in this report is segmented –

    1) By Product: Software, Devices, Services

    2) By Distribution Channel: Online Platforms, Direct-To-Consumer Digital Channels, Other Distribution Channels

    3) By Application: Muscle Strengthening, Physical Activity Monitoring, Nutrition Management, Other Applications

    4) By End User: Hospitals And Clinics, Homecare Settings, Rehabilitation Centers, Other End Users

    Subsegments:

    1) By Software: Mobile Applications, Web-Based Platforms, AI-Powered Monitoring Tools, Exercise And Rehabilitation Programs, Nutritional Guidance Software

    2) By Devices: Wearable Fitness Trackers, Smart Scales, Connected Resistance Bands, Electromyography (EMG) Devices, Muscle Strength Assessment Tools

    3) By Services: Remote Patient Monitoring Services, Virtual Physiotherapy Sessions, Teleconsultation Services, Personalized Coaching Services, Data Analytics And Reporting Services

    Which Trends Are Impacting The Progress Of The Digital Therapeutics Sarcopenia Market?

    Leading companies in the digital therapeutics sarcopenia market are concentrating on developing sophisticated solutions, such as drug discovery platforms. Their objective is to create more targeted therapies, improve treatment effectiveness, and accelerate the provision of personalized care for age-related muscle loss. A drug discovery platform aids in the quicker and more effective identification and creation of new drugs through advanced tools and methods. For example, in April 2025, ProFuse Technology, an Israel-based biotechnology company, unveiled a new drug discovery platform aimed at preventing muscle loss induced by GLP-1 weight-loss drugs, aging (sarcopenia), and cancer cachexia. By employing lab-grown, highly mature muscle tissues that accurately imitate natural muscle, the company can precisely test and screen drug candidates with enhanced speed and efficiency. This advanced platform reduces the dependence on animal testing and decreases research expenses. As the demand for muscle-preserving therapies rises, ProFuse is broadening its scope beyond cultivated meat into the biopharmaceutical industry, offering a pioneering strategy to address increasingly complex muscle health issues.

    Who Are The Companies Competing Within The Digital Therapeutics Sarcopenia Market?

    Major companies operating in the digital therapeutics sarcopenia market are Sword Health Inc., Biofourmis Inc., Hinge Health Inc., Omada Health Inc., Evolv Rehabilitation Technologies Ltd., Click Therapeutics Inc., DarioHealth Corp., WellDoc Inc., Lark Technologies Inc., Kaia Health Software GmbH, Liva Healthcare A/S, Zibrio Inc., Gait Up SA, Noraxon Inc., Mira Rehab Limited, Cometa Srl., Koneksa Health Inc., Physitrack PLC, Kaia Health Inc., XRHealth USA Inc., MedRhythms Inc.

    Get The Full Digital Therapeutics Sarcopenia Market Report:

    https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

    Which Region Leads The Digital Therapeutics Sarcopenia Market In Overall Market Size?

    North America was the largest region in the digital therapeutics sarcopenia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital therapeutics sarcopenia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Digital Therapeutics Sarcopenia Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

    Browse Through More Reports Similar to the Global Digital Therapeutics Sarcopenia Market 2026, By The Business Research Company

    Battery Separators Market Report 2026

    https://www.thebusinessresearchcompany.com/report/battery-separators-global-market-report

    Cutter Stapler Market Report 2026

    https://www.thebusinessresearchcompany.com/report/cutter-stapler-global-market-report

    Battery Manufacturing Equipment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/battery-manufacturing-equipment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Digital Therapeutics for Sarcopenia Market to Reach $3.21B by 2030

    Digital Therapeutics for Sarcopenia Market to Reach $3.21B by 2030

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Is The Estimated Market Size Of The Digital Therapeutics Sarcopenia Market In 2026, And How Will Its Value Evolve By 2030?

    The digital therapeutics sarcopenia market size has seen rapid expansion in recent years. It is anticipated to increase from $1.54 billion in 2025 to $1.78 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 16.1%. The growth observed historically can be ascribed to elements such as the increasing prevalence of an aging population, heightened awareness of health risks linked to sarcopenia, the expansion of telehealth adoption, increasing acceptance of software-based medical therapies, and the early clinical validation of digital interventions.

    The digital therapeutics sarcopenia market size is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $3.21 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.9%. This projected growth throughout the forecast period stems from factors such as the heightened demand for home-based care for chronic conditions, the escalating incorporation of AI-powered personalized therapies, broadened reimbursement avenues for digital therapeutics, the expanding uptake of remote patient monitoring, and a reinforced emphasis on solutions for preventive muscle health. Key trends anticipated during this period encompass the wider acceptance of tailored digital therapy programs, the increased utilization of wearable devices for muscle monitoring, the broader implementation of remote physiotherapy platforms, the development of data-informed sarcopenia management strategies, and a stronger commitment to patient involvement and compliance.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

    What Major Factors Are Driving The Digital Therapeutics Sarcopenia Market Forward?

    The expanding presence of comorbidities is anticipated to fuel the expansion of the digital therapeutics sarcopenia market. Comorbidities are defined as the concurrent existence of multiple health conditions within a single individual. The increase in comorbidities stems from an aging demographic, as older age raises the probability of developing several chronic ailments due to diminishing physiological functions and extended exposure to various health hazards. Digital therapeutics designed for sarcopenia offer advantages in averting comorbidities, particularly obesity, by fostering consistent physical activity and muscle reinforcement, which aids in enhancing metabolism and minimizing fat accumulation. For example, data from March 2024, provided by the World Obesity Federation, a membership body based in the UK, projects that nearly 79% of adults impacted by overweight and obesity will reside in low- and middle-income nations by 2035, with the total count of obese adults forecast to reach 1.53 billion. Consequently, the increasing incidence of comorbidities is propelling the growth of the digital therapeutics sarcopenia market.

    How Are Segments Identified Within The Digital Therapeutics Sarcopenia Market Segment Framework?

    The digital therapeutics sarcopenia market covered in this report is segmented –

    1) By Product: Software, Devices, Services

    2) By Distribution Channel: Online Platforms, Direct-To-Consumer Digital Channels, Other Distribution Channels

    3) By Application: Muscle Strengthening, Physical Activity Monitoring, Nutrition Management, Other Applications

    4) By End User: Hospitals And Clinics, Homecare Settings, Rehabilitation Centers, Other End Users

    Subsegments:

    1) By Software: Mobile Applications, Web-Based Platforms, AI-Powered Monitoring Tools, Exercise And Rehabilitation Programs, Nutritional Guidance Software

    2) By Devices: Wearable Fitness Trackers, Smart Scales, Connected Resistance Bands, Electromyography (EMG) Devices, Muscle Strength Assessment Tools

    3) By Services: Remote Patient Monitoring Services, Virtual Physiotherapy Sessions, Teleconsultation Services, Personalized Coaching Services, Data Analytics And Reporting Services

    Which Trends Are Impacting The Progress Of The Digital Therapeutics Sarcopenia Market?

    Leading companies in the digital therapeutics sarcopenia market are concentrating on developing sophisticated solutions, such as drug discovery platforms. Their objective is to create more targeted therapies, improve treatment effectiveness, and accelerate the provision of personalized care for age-related muscle loss. A drug discovery platform aids in the quicker and more effective identification and creation of new drugs through advanced tools and methods. For example, in April 2025, ProFuse Technology, an Israel-based biotechnology company, unveiled a new drug discovery platform aimed at preventing muscle loss induced by GLP-1 weight-loss drugs, aging (sarcopenia), and cancer cachexia. By employing lab-grown, highly mature muscle tissues that accurately imitate natural muscle, the company can precisely test and screen drug candidates with enhanced speed and efficiency. This advanced platform reduces the dependence on animal testing and decreases research expenses. As the demand for muscle-preserving therapies rises, ProFuse is broadening its scope beyond cultivated meat into the biopharmaceutical industry, offering a pioneering strategy to address increasingly complex muscle health issues.

    Who Are The Companies Competing Within The Digital Therapeutics Sarcopenia Market?

    Major companies operating in the digital therapeutics sarcopenia market are Sword Health Inc., Biofourmis Inc., Hinge Health Inc., Omada Health Inc., Evolv Rehabilitation Technologies Ltd., Click Therapeutics Inc., DarioHealth Corp., WellDoc Inc., Lark Technologies Inc., Kaia Health Software GmbH, Liva Healthcare A/S, Zibrio Inc., Gait Up SA, Noraxon Inc., Mira Rehab Limited, Cometa Srl., Koneksa Health Inc., Physitrack PLC, Kaia Health Inc., XRHealth USA Inc., MedRhythms Inc.

    Get The Full Digital Therapeutics Sarcopenia Market Report:

    https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

    Which Region Leads The Digital Therapeutics Sarcopenia Market In Overall Market Size?

    North America was the largest region in the digital therapeutics sarcopenia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital therapeutics sarcopenia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Digital Therapeutics Sarcopenia Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

    Browse Through More Reports Similar to the Global Digital Therapeutics Sarcopenia Market 2026, By The Business Research Company

    Battery Separators Market Report 2026

    https://www.thebusinessresearchcompany.com/report/battery-separators-global-market-report

    Cutter Stapler Market Report 2026

    https://www.thebusinessresearchcompany.com/report/cutter-stapler-global-market-report

    Battery Manufacturing Equipment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/battery-manufacturing-equipment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Sarcopenia Treatment Market Revenue Growth Expected to Reach $4.97 Billion by 2030 with 6% CAGR

    Sarcopenia Treatment Market Revenue Growth Expected to Reach $4.97 Billion by 2030 with 6% CAGR

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Will Be The Estimated Market Valuation Of The Sarcopenia Treatment Market By The End Of 2030?

    The sarcopenia treatment market has experienced robust expansion in recent years. This market is expected to increase from $3.72 billion in 2025 to $3.94 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.9%. The growth witnessed during the historic period stems from factors such as an expanding elderly population base, greater understanding of age-related muscle deterioration, dependence on physical therapy and nutritional assistance, the restricted availability of approved pharmaceutical interventions, and an escalation in mobility-related conditions.

    The sarcopenia treatment market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach $4.97 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.0%. This forecasted growth is largely driven by the emergence of new pharmacological therapies, a heightened emphasis on timely diagnosis and intervention, increased healthcare expenditure directed towards elderly care, the rising occurrence of chronic illnesses impacting muscle health, and the proliferation of clinical trials focused on muscle regeneration. Key developments expected during this period involve a greater uptake of combined pharmaceutical and exercise-driven approaches, the growing incorporation of nutritional supplements in managing sarcopenia, an increase in clinical investigations into myostatin inhibitors and anabolic agents, enhanced identification of sarcopenia among older adults, and the broader inclusion of physical therapy within treatment protocols.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13926&type=smp

    What Drivers Are Shaping The Future Growth Of The Sarcopenia Treatment Market?

    An anticipated increase in malnutrition is projected to drive the expansion of the sarcopenia treatment market in the future. Malnutrition encompasses an individual’s inadequate, excessive, or imbalanced consumption of energy and nutrients, including conditions like undernutrition, overweight, obesity, and diet-related noncommunicable illnesses. Sarcopenia treatments aim to tackle the concurrent issues of malnutrition and sarcopenia among elderly individuals using approaches like nutritional intervention and physical activity, with the goal of enhancing muscle mass, physical strength, and general nutritional well-being. As an illustration, a report released by the United States Department of Agriculture, a US-based government entity, indicated in January 2025 that household food insecurity affected 17.9% of families with children in 2023, impacting approximately 6.5 million similar households. Consequently, the increasing prevalence of malnutrition is fueling the development of the sarcopenia treatment market.

    Which Segment Classifications Shape The Sarcopenia Treatment Market?

    The sarcopenia treatment market covered in this report is segmented –

    1) By Treatment Type: Protein Supplements, Vitamin B12 Supplements, Vitamin D And Calcium Supplements, Other Treatment Types

    2) By Type: Primary Sarcopenia, Secondary Sarcopenia

    3) By Route Of Administration: Oral, Parenteral, Enteral

    4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

    Subsegments:

    1) By Protein Supplements: Whey Protein, Casein Protein, Soy Protein, Plant-Based Protein

    2) By Vitamin B12 Supplements: Cyanocobalamin, Methylcobalamin

    3) By Vitamin D And Calcium Supplements: Vitamin D2, Vitamin D3, Calcium Carbonate, Calcium Citrate

    4) By Other Treatment Types: Exercise Programs, Hormone Replacement Therapy, Other Nutritional Interventions

    What Major Market Trends Are Driving Changes In The Sarcopenia Treatment Market?

    Leading entities within the sarcopenia treatment market are intensifying their efforts to develop various advanced clinical studies, aiming to provide improved treatment alternatives. A clinical study, by definition, involves a structured investigation with human participants to assess the safety, effectiveness, or results of a medical intervention. For example, in September 2023, Biophytis, a biotechnology firm based in France, received authorization from the Food and Drug Administration (FDA) to commence its SARA-31 Phase 3 study focusing on sarcopenia. This particular study is designed to assess the efficacy and safety of Sarconeos (BIO101) when used to treat sarcopenic individuals facing a risk of motor disability. It represents a notable leap forward in both technological and pharmaceutical treatment strategies, potentially delivering benefits in terms of efficacy and safety for patients suffering from severe sarcopenia. Notably, it marks the first Phase 3 study ever conducted for sarcopenia, having secured FDA authorization. Approximately 900 patients, all over 65 years old and presenting with sarcopenia, reduced walking speed, and diminished hand grip strength, will participate in the study. The main objective, or primary endpoint, involves evaluating the risk of major mobility disability (MMD), along with walking speed, hand grip strength, and the patients’ self-reported quality of life.

    Which Companies Are Expanding Their Footprint In The Sarcopenia Treatment Market?

    Major companies operating in the sarcopenia treatment market are Pfizer Inc, F Hoffmann La Roche, Merck Sharp And Dohme Corp, AbbVie Inc, Bayer AG, Novartis AG, Sanofi SA, Abbott Laboratories Inc, GlaxoSmithKline plc, Eli Lilly And Company, BASF SE, Nestle Health Science, Haleon Group Of Companies, DSM, Amway Corporation, Perrigo Company PLC, Intas Pharmaceuticals Ltd, Zydus Lifesciences, Fermenta Biotech Limited, Metagenics LLC, Makers Nutrition LLC, NutraScience Labs, AstaReal AB, NutraPak USA, BioThrive Sciences, Wellona Pharma, Healing Pharma India Pvt Ltd, Nutrafill

    Read the full sarcopenia treatment market report here:

    https://www.thebusinessresearchcompany.com/report/sarcopenia-treatment-global-market-report

    Which Geographic Regions Are Influencing Demand In The Sarcopenia Treatment Market?

    North America was the largest region in the sarcopenia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sarcopenia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Sarcopenia Treatment Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=13926&type=smp

    Browse Through More Reports Similar to the Global Sarcopenia Treatment Market 2026, By The Business Research Company

    Sarcoma Drugs Global Market Report

    https://www.thebusinessresearchcompany.com/report/sarcoma-drugs-global-market-report

    Congenital Diaphragmatic Hernia Drugs Global Market Report

    https://www.thebusinessresearchcompany.com/report/congenital-diaphragmatic-hernia-drugs-global-market-report

    Vulvodynia Treatment Global Market Report

    https://www.thebusinessresearchcompany.com/report/vulvodynia-treatment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Digital Therapeutics Sarcopenia Market Revenue Growth Expected to Reach $3.21 Billion by 2030 with 15.9% CAGR

    Digital Therapeutics Sarcopenia Market Revenue Growth Expected to Reach $3.21 Billion by 2030 with 15.9% CAGR

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    How Much Is The Digital Therapeutics Sarcopenia Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

    The digital therapeutics sarcopenia market size has experienced rapid growth in recent years. It is projected to expand from $1.54 billion in 2025 to $1.78 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 16.1%. This historical growth can be ascribed to factors such as the rising prevalence of the aging population, increased awareness regarding sarcopenia-related health risks, the expansion of telehealth adoption, growing acceptance of software-based medical therapies, and the early clinical validation of digital interventions.

    The digital therapeutics sarcopenia market size is projected to experience substantial growth in the upcoming years, with an expectation to reach $3.21 billion by 2030, advancing at a compound annual growth rate (CAGR) of 15.9%. This anticipated growth is primarily driven by factors such as the increasing demand for home-based chronic condition management, the rising integration of AI-driven therapeutic personalization, the expansion of reimbursement support for digital therapeutics, the growing adoption of remote patient monitoring, and an increasing focus on preventive muscle health solutions. Major trends anticipated in this forecast period include the increasing adoption of personalized digital therapy programs, the rising use of wearable-integrated muscle monitoring, the growing deployment of remote physiotherapy platforms, the expansion of data-driven sarcopenia management solutions, and an enhanced focus on patient engagement and adherence.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=27278&type=smp

    What Major Drivers Are Influencing Demand In The Digital Therapeutics Sarcopenia Market?

    The increasing incidence of comorbidities is anticipated to drive the expansion of the digital therapeutics sarcopenia market. Comorbidities are defined as the concurrent presence of two or more health issues within an individual. This rise in comorbidities is linked to an aging demographic, where older age naturally leads to a greater chance of developing several chronic conditions because of deteriorating bodily functions and prolonged exposure to health hazards. Digital therapeutics designed for sarcopenia offer advantages in averting comorbidities, particularly obesity, through encouraging consistent physical activity and muscle building, which in turn boosts metabolism and diminishes fat buildup. As an illustration, the World Obesity Federation, a UK-based membership organization, reported in March 2024 that by 2035, close to 79% of adults experiencing overweight and obesity are projected to reside in low- and middle-income countries, with the total count of obese adults estimated to reach 1.53 billion. Consequently, the growing frequency of comorbidities is fueling the expansion of the digital therapeutics sarcopenia market.

    What Major Segment Divisions Exist Within The Digital Therapeutics Sarcopenia Market?

    The digital therapeutics sarcopenia market covered in this report is segmented –

    1) By Product: Software, Devices, Services

    2) By Distribution Channel: Online Platforms, Direct-To-Consumer Digital Channels, Other Distribution Channels

    3) By Application: Muscle Strengthening, Physical Activity Monitoring, Nutrition Management, Other Applications

    4) By End User: Hospitals And Clinics, Homecare Settings, Rehabilitation Centers, Other End Users

    Subsegments:

    1) By Software: Mobile Applications, Web-Based Platforms, AI-Powered Monitoring Tools, Exercise And Rehabilitation Programs, Nutritional Guidance Software

    2) By Devices: Wearable Fitness Trackers, Smart Scales, Connected Resistance Bands, Electromyography (EMG) Devices, Muscle Strength Assessment Tools

    3) By Services: Remote Patient Monitoring Services, Virtual Physiotherapy Sessions, Teleconsultation Services, Personalized Coaching Services, Data Analytics And Reporting Services

    What Major Market Trends Are Driving Changes In The Digital Therapeutics Sarcopenia Market?

    Key players within the digital therapeutics sarcopenia market are concentrating on advancing solutions, particularly drug discovery platforms, to formulate more precise therapies, improve treatment efficacy, and speed up the provision of tailored care for muscle loss associated with aging. A drug discovery platform aids in the quicker and more effective identification and creation of new medications by utilizing advanced instruments and techniques. For example, in April 2025, ProFuse Technology, an Israel-based biotechnology enterprise, introduced a new drug discovery platform specifically targeting the prevention of muscle loss induced by GLP-1 weight-loss drugs, aging (sarcopenia), and cancer cachexia. By employing lab-cultivated, highly mature muscle tissues that emulate natural muscle, the company is able to accurately test and screen drug candidates with greater speed and efficiency. This sophisticated platform diminishes reliance on animal testing and reduces research expenditures. As therapies aimed at preserving muscle become more sought after, ProFuse is expanding its focus beyond cultivated meat into biopharma, providing an innovative strategy to address the increasing challenges related to muscle health.

    Which Companies Are Leading Innovation In The Digital Therapeutics Sarcopenia Market?

    Major companies operating in the digital therapeutics sarcopenia market are Sword Health Inc., Biofourmis Inc., Hinge Health Inc., Omada Health Inc., Evolv Rehabilitation Technologies Ltd., Click Therapeutics Inc., DarioHealth Corp., WellDoc Inc., Lark Technologies Inc., Kaia Health Software GmbH, Liva Healthcare A/S, Zibrio Inc., Gait Up SA, Noraxon Inc., Mira Rehab Limited, Cometa Srl., Koneksa Health Inc., Physitrack PLC, Kaia Health Inc., XRHealth USA Inc., MedRhythms Inc.

    Read the full digital therapeutics sarcopenia market report here:

    https://www.thebusinessresearchcompany.com/report/digital-therapeutics-sarcopenia-global-market-report

    Which Region Shows The Strongest Potential For Future Growth In The Digital Therapeutics Sarcopenia Market?

    North America was the largest region in the digital therapeutics sarcopenia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital therapeutics sarcopenia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Digital Therapeutics Sarcopenia Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=27278&type=smp

    Browse Through More Reports Similar to the Global Digital Therapeutics Sarcopenia Market 2026, By The Business Research Company

    Cutter Stapler Global Market Report

    https://www.thebusinessresearchcompany.com/report/cutter-stapler-global-market-report

    Battery Manufacturing Equipment Global Market Report

    https://www.thebusinessresearchcompany.com/report/battery-manufacturing-equipment-global-market-report

    Battery Separators Global Market Report

    https://www.thebusinessresearchcompany.com/report/battery-separators-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model